Assessing inhaled corticosteroid adherence and responsiveness in severe asthma using beclometasone dipropionate/formoterol NEXThaler™ dose-counting and nitric oxide monitoring
Aung, Hnin Balasundaram, Kumaran Bell, Mark Bradding, Peter Boddy, Claire E Hampson, Eleanor Murphy, Anna Naveed, Shamsa Parnell, Lauren
Aung, Hnin
Balasundaram, Kumaran
Bell, Mark
Bradding, Peter
Boddy, Claire E
Hampson, Eleanor
Murphy, Anna
Naveed, Shamsa
Parnell, Lauren
Abstract
Background: 65% of people with severe asthma and a FeNO ≥45 ppb are non-adherent to inhaled corticosteroids (ICS). Digital devices recording both time-of-use and inhaler technique identify non-adherence and ICS responsiveness but are not widely available. As the NEXThaler™ dose counter only activates at an inspiratory flow of 35 L/min, this may provide an alternative to identifying ICS responsiveness.
Objective: To assess ICS adherence and responsiveness in severe asthma using beclometasone/formoterol (200/6 mcg) NEXThaler™ (BFN) dose-counting.
Methods: Severe asthmatics with a FeNO ≥45 ppb were invited to use BFN in place of their usual ICS/long-acting β2-agonist (LABA). FeNO, ACQ6, lung function and blood eosinophil count were monitored for 3 months. A log10ΔFeNO ≥0.24 was used to define FeNO suppression as the primary marker of ICS responsiveness at day 28.
Results: 27/48 (56%) patients demonstrated significant FeNO suppression at month 1 (median pre-114, post-48 ppb, p<0.001). A small but significant reduction occurred in FeNO non-suppressors. ACQ6 fell a median 1.2 units in FeNO suppressors (p<0.001) and 0.5 units in non-suppressors (p=0.025). These effects were sustained until month 3 in FeNO suppressors with a significant improvement in FEV1 and blood eosinophils. 67% (18/27) of those with baseline ICS/LABA prescription refills of ≥80% were FeNO suppressors suggesting prior non-adherence despite adequate prescription collection. 79% of FeNO suppressors did not require biologics within mean 11.4 months from initial dose counting.
Conclusion: BFN dose counting identifies ICS responsiveness in severe asthma with the implication that these patients may not need to progress to biological therapies.
MIDER Authors
Citations
Altmetric:
Date
Type
Article
Subject
Adherence, FeNO, NEXThaler™, Severe asthma
Collections
Citation
Aung, H. W., Boddy, C. E., Hampson, E., Bell, M., Parnell, L. A., Balasundaram, K., Murphy, A. C., Naveed, S., & Bradding, P. (2024). Assessing inhaled corticosteroid adherence and responsiveness in severe asthma using beclometasone dipropionate/formoterol NEXThaler™ dose-counting and nitric oxide monitoring. The journal of allergy and clinical immunology. In practice, S2213-2198(24)00288-5. Advance online publication. https://doi.org/10.1016/j.jaip.2024.03.026